News Breaks |
|
|
| August 28, 2012 |
| 08:58 EDT |  | ZNH, LLY, ASEI, MTX, HCBK | On The Fly: Analysts Upgrade Summary
Today's noteworthy upgrades include: Eli Lilly (LLY) upgraded to Overweight from Underweight at Atlantic Equities...Hudson City Bancorp (HCBK) upgraded to Outperform from Underperform at RBC Capital...American Science & Engineering (ASEI) upgraded to Buy from Hold at Benchmark Co...China Southern Airlines (ZNH) upgraded to Neutral from Sell at Citigroup...Minerals Technologies (MTX) upgraded to Overweight from Equal Weight at First Analysis. |
|
|
News For LLY;HCBK;ASEI;ZNH;MTX From The Last 14 Days Check below for free stories on LLY;HCBK;ASEI;ZNH;MTX the last two weeks. |
|
|
| May 16, 2013 |
| 08:55 EDT |  | LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
 Subscribe for More Information |
|
| May 14, 2013 |
| 09:09 EDT |  | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information |
|
| 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 11:48 EDT |  | LLY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 08:02 EDT | | LLY | Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint
Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. |
|
| May 9, 2013 |
| 11:01 EDT | | LLY | Sears Holdings names Jeff Balagna Chief Information Officer
Subscribe for More Information |
|
| May 7, 2013 |
| 16:08 EDT | | ASEI | American Science & Engineering announces $35M repurchase program
American Science & Engineering announced that its board has authorized another $35M stock repurchase program. The company will implement a Rule 10b5-1 trading plan to make such purchases. Any repurchased shares will be funded with cash on hand. The new program will not commence until after the completion of the company's current blackout period and existing stock repurchase program which the company announced on August 2, 2012. |
|
| 16:06 EDT |  | ASEI | American Science & Engineering reports Q4 EPS ex-charge 57c, consensus 66c
Subscribe for More Information |
|
| May 6, 2013 |
| 18:42 EDT | | LLY | Eli Lilly and Boehringer announce results from Phase 3 study of linagliptin
Subscribe for More Information |
|
| 16:40 EDT | | LLY | Eli Lilly announces CEO Dr. John Lechleiter to undergo surgery
Subscribe for More Information |
| |
|
|
|
|
